Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia

MeSH terms

• Aged
• Aged, 80 and over
• Angiogenesis Inhibitors / administration & dosage
• Angiogenesis Inhibitors / adverse effects
• Angiogenesis Inhibitors / therapeutic use
• Diarrhea / chemically induced
• Drug Administration Schedule
• Fatigue / chemically induced
• Female
• Humans
• Indoles / administration & dosage
• Indoles / adverse effects
• Indoles / therapeutic use*
• Kaplan-Meier Estimate
• Leukemia, Myelomonocytic, Chronic / drug therapy*
• Leukemia, Myelomonocytic, Chronic / pathology
• Male
• Middle Aged
• Myelodysplastic Syndromes / drug therapy*
• Myelodysplastic Syndromes / pathology
• Pyrroles / administration & dosage
• Pyrroles / adverse effects
• Pyrroles / therapeutic use*
• Remission Induction
• Sunitinib
• Thrombocytopenia / chemically induced
• Treatment Outcome